Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile Unknown unknown
Therapy Buparlisib
Indication/Tumor Type triple-receptor negative breast cancer
Response Type no benefit

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown triple-receptor negative breast cancer no benefit Buparlisib Phase II Actionable In a Phase II trial, Buparlisib (BKM120) treatment in patients with triple-negative breast cancer (TNBC) resulted in median progression-free survival of 1.8 months, median overall survival of 11.2 months, stable disease lasting more than four months in 12% (6/50) of patients, and no objective responses, and due to the limited clinical efficacy, further study as a single agent in TNBC patients was not supported (PMID: 33138866; NCT01790932, NCT01629615). 33138866
PubMed Id Reference Title Details
(33138866) Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Full reference...